Amgen Buries Second FDA Action Letter For Bone Drug in Cancer Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
HALT! More bad news: Complete Response letter from Agency this week requests new studies in treatment induced bone loss.
You may also be interested in...
New Oncology Indications Should Continue Denosumab’s Upward Trajectory
Already on an upward trajectory in oncology uses, Amgen’s denosumab, known as Prolia and Xgeva, got a bit of a boost with FDA approval of two new indications for treatment-induced bone loss in prostate and breast cancer – though neither is expected to add much to the bottom line.
New Oncology Indications Should Continue Denosumab’s Upward Trajectory
Already on an upward trajectory in oncology uses, Amgen’s denosumab, known as Prolia and Xgeva, got a bit of a boost with FDA approval of two new indications for treatment-induced bone loss in prostate and breast cancer – though neither is expected to add much to the bottom line.
New Oncology Indications Give Amgen's Bone Drug Denosumab A Bit Of A Leg Up
Concerns laid out in "complete response" letter were addressed with data from other trials.